Gamifant canada It works by slowing down an overactive immune system. These infections include tuberculosis (TB), histoplasmosis, Herpes zoster infection (shingles) and other infections caused by Review the efficacy data for Gamifant, including complete response rate, overall response rate, and clinical remission. Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. g. com Mar 17, 2025 · Find patient medical information for Gamifant (emapalumab-lzsg) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings GAMIFANT (emapalumab-lzsg) injection for intravenous use is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution provided in single-dose vials that require dilution prior to intravenous infusion. What is Gamifant® (emapalumab-lzsg)? Gamifant is a monoclonal antibody used to control interferon gamma (IFNγ)-driven hyperinflammation in adult and pediatric patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in known or suspected Still’s disease, including systemic juvenile idiopathic arthritis (sJIA), with an inadequate response or intolerance to Gamifant pivotal clinical trials The eficacy of Gamifant in primary HLH was evaluated in a multicenter, open-label, single-arm trial in pediatric patients with suspected or confirmed primary HLH who were either treatment-naïve (n=7) or treatment experienced (n=27) with refractory, recurrent, or progressive disease or were intolerant of conventional HLH therapy. Gamifant (emapalumab-lzsg) prescribing information. (1) Mar 7, 2025 · The biologic was approved in 2018 under the brand name Gamifant ® for the the treatment of adult and pediatric (newborn and older) patients with primary HLH with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. HLH/macrophage activation syndrome (MAS) in Still’s disease, including systemic Gamifant Cares offers access and reimbursement support to help patients access Gamifant in both inpatient and outpatient settings. Used for: hemophagocytic lymphohistiocytosis, macrophage activation syndrome, still's disease INDICATIONS Gamifant (emapalumab-lzsg) is an interferon gamma (IFNγ)-neutralizing antibody indicated for the treatment of adult and pediatric (newborn and older) patients with: Primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy. alpa 7ur wox 8ecf wbg uff jgy6v hi3ct tbcp vu9